Chimerix Completes Phase I Study And Initiates A Phase II Multi-Dose Clinical Trial For CMX001 - CMX001 is an Orally Available Broad Spectrum Antiviral Being Investigated for the Treatment of dsDNA Viruses Including Smallpox, BK Virus, CMV and Adenovirus - RESEARCH TRIANGLE PARK, NC, January 6,
Chimerix Initiates A Multi-Dose Clinical Trial Of The Company’s Lead Compound, CMX001, For The Treatment For Smallpox Infection RESEARCH TRIANGLE PARK, NC, December 11, 2007 - Chimerix, Inc., a biotechnology company developing orally available antiviral therapeutics, announced today that the
Merial To Screen Chimerix' Chemical Library For Animal Health Drug Leads DULUTH, GA, and RESEARCH TRIANGLE PARK, NC, January 29, 2007 - Merial Limited and Chimerix, Inc. announced today that they have signed an agreement under which Merial will screen a Chimerix chemical library for animal health
Chimerix Announced Initiation of Phase I clinical trials of CMX001, An Oral Treatment for Smallpox Infection RESEARCH TRIANGLE PARK, NC, June 28 2006 - Chimerix, Inc., a biotechnology company developing orally available antiviral therapeutics, announced today that it has received U.S.
Chimerix Acquires Lead Compound Library of Antiviral Agents from University of Michigan RESEARCH TRIANGLE PARK, NC, May 24 2006 - Chimerix, Inc., an emerging biotechnology company developing orally available antiviral therapeutics, announced today that it has acquired Dr.
Chimerix and USAMRIID Collaborate to Complete Preclinical Development of Smallpox Therapeutic RESEARCH TRIANGLE PARK, NC, April 18, 2006 - Chimerix, Inc., a biotechnology company developing orally available, targeted medicines to treat smallpox and other viral infections, announced today that it
